Press Releases

Enrollment in CARPO, Phase 2b trial of Auxora™ in acute pancreatitis (AP), on track with topline data expected in 2Q 2024   Auxora granted Investigational New Drug clearance by the FDA for Phase 2 trial in severe acute kidney injury (AKI); KOURAGE initiating in 2Q 2024 CRSPA Phase 1/2 trial of

Therapeutic treatment with Auxora shown to hasten the recovery of kidney function and improve survival in a rat model of acute kidney injury (AKI) Preclinical results are consistent with clinical observations made with Auxora, supporting the KOURAGE trial in patients with severe AKI that will start

Preclinical data show that therapeutic treatment with Auxora in a rat model of AKI improves kidney function as measured by glomerular filtration rate LA JOLLA, Calif. , Feb. 28, 2024 /PRNewswire/ -- CalciMedica Inc. ( CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical

Phase 2 trial, expected to begin in 1H 2024, aims to address the unmet medical need of patients suffering from stage 2 or 3 acute kidney injury with associated acute hypoxemic respiratory failure, a condition associated with a high mortality rate Development of Auxora in AKI is supported by both

LA JOLLA, Calif. , Feb. 7, 2024 /PRNewswire/ -- CalciMedica Inc. (" CalciMedica ") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic

$20.4 million in upfront financing with the potential to receive up to an additional approximately $34.2 million for an aggregate of up to approximately $55 million   Upfront net proceeds to provide funds to expand Auxora ™ clinical development to include planned Phase 2 acute kidney injury (AKI)